Nykode Therapeutics AS (OSL:NYKD) Debt-to-Equity : 0.03 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nykode Therapeutics AS Debt-to-Equity?

Nykode Therapeutics AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr14.51 Mil. Nykode Therapeutics AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr24.07 Mil. Nykode Therapeutics AS's Total Stockholders Equity for the quarter that ended in Dec. 2024 was kr1,528.38 Mil. Nykode Therapeutics AS's debt to equity for the quarter that ended in Dec. 2024 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nykode Therapeutics AS's Debt-to-Equity or its related term are showing as below:

OSL:NYKD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 0.04
Current: 0.03

During the past 8 years, the highest Debt-to-Equity Ratio of Nykode Therapeutics AS was 0.04. The lowest was 0.00. And the median was 0.03.

OSL:NYKD's Debt-to-Equity is ranked better than
81.2% of 1016 companies
in the Biotechnology industry
Industry Median: 0.145 vs OSL:NYKD: 0.03

Nykode Therapeutics AS Debt-to-Equity Historical Data

The historical data trend for Nykode Therapeutics AS's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nykode Therapeutics AS Debt-to-Equity Chart

Nykode Therapeutics AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.03

Nykode Therapeutics AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.03	0.03	0.03	0.03

Competitive Comparison of Nykode Therapeutics AS's Debt-to-Equity

For the Biotechnology subindustry, Nykode Therapeutics AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nykode Therapeutics AS's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Nykode Therapeutics AS Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nykode Therapeutics AS's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(14.508	+	24.068)	/	1528.376
	=	0.03

Nykode Therapeutics AS's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(14.508	+	24.068)	/	1528.376
	=	0.03

Nykode Therapeutics AS (OSL:NYKD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nykode Therapeutics AS Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nykode Therapeutics AS's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nykode Therapeutics AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nykode Therapeutics AS (OSL:NYKD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VACBF:USA 5VB:Germany

Address

Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349

Website

https://www.nykode.com

Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.

Nykode Therapeutics AS Headlines

No Headlines